{
  "pmcid": "10527167",
  "sha256": "ca1cd6b7fe107aa41fd62c31040a14e46c6dff5807161ce933883b51f1be9583",
  "timestamp_utc": "2025-11-09T23:07:24.356910+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.791660516605166,
    "reading_ease": 18.9735708203236,
    "word_count": 271
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Patient-Reported Symptomatic Adverse Events in Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "patients with borderline resectable pancreatic ductal adenocarcinoma were randomised to receive either 8 doses of mFOLFIRINOX (Arm 1) or 7 doses of mFOLFIRINOX plus hypofractionated radiotherapy (Arm 2)"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with borderline resectable pancreatic ductal adenocarcinoma"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive either 8 doses of mFOLFIRINOX (Arm 1) or 7 doses of mFOLFIRINOX plus hypofractionated radiotherapy (Arm 2)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate symptomatic adverse event (AE) rates using the Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) among patients with pancreatic cancer receiving neoadjuvant therapy."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the frequency of symptomatic AEs, measured throughout the treatment period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not specified."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "In trial A021501, conducted from December 31, 2016, to January 1, 2019, patients with borderline resectable pancreatic ductal adenocarcinoma were randomised"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 126 patients, 96 initiated treatment and completed a baseline plus at least one post-baseline PRO-CTCAE assessment."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Decreased appetite was higher in Arm 2 than in Arm 1 (P = 0.0497)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Diarrhea and fatigue were the only symptomatic grade 3 or higher AEs identified in at least 10% of patients using CTCAE."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCTXXXXXXX."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Supported by [Funding Source]."
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}